Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17958020 | 0.92 | RIPK1 (0.51) | MEN1KMT2ARIPK1NPC1RAB9A | |
| SCHEMBL17960511 | 0.81 | HDAC6 (0.58) | RIPK1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL17960436 | 0.81 | HDAC6 (0.48) | RIPK1LMNAHPGDSMN1; SMN2HDAC6 | |
| SCHEMBL17973610 | 0.80 | HDAC6 (0.46) | RIPK1NPC1RAB9AHPGDHDAC6 | |
| SCHEMBL17957700 | 0.80 | NPC1 (0.47) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL17960478 | 0.78 | HDAC6 (0.66) | RIPK1HDAC6HDAC8HDAC1 | |
| SCHEMBL17960446 | 0.78 | ALDH1A1 (0.49) | RIPK1LMNAHPGDSMN1; SMN2HDAC6 | |
| SCHEMBL17957672 | 0.77 | BLM (0.55) | RIPK1NPC1RAB9ASMN1; SMN2HDAC8 | |
| SCHEMBL17957583 | 0.77 | HDAC6 (0.46) | RIPK1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL17960295 | 0.77 | HDAC6 (0.51) | MEN1KMT2ARIPK1HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221972-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221972-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | CYP1A2 2757/4885CYP2C9 4107/4885CYP2C19 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.